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Background: Automated cellular analyzers are expected to improve the analytical perfor-
mance in body fluid (BF) analysis. We evaluated the analytical performance of three auto-
mated cellular analyzers and established optimum reflex analysis guidelines.
Methods: A total of 542 BF samples (88 cerebrospinal fluid [CSF] samples and 454 non-
CSF samples) were examined using manual counting and three automated cellular ana-
lyzers: UniCel DxH 800 (Beckman Coulter), XN-350 (Sysmex), and UF-5000 (Sysmex). 
Additionally, 2,779 BF analysis results were retrospectively reviewed. For malignant cell 
analysis, the receiver operating characteristic (ROC) curve was used, and the detection of 
high fluorescence-BF cells (HF-BFs) using the XN-350 analyzer was compared with cytol-
ogy results.
Results: All three analyzers showed good agreement for total nucleated cell (TNC) and 
red blood cell (RBC) counts, except for the RBC count in CSF samples using the UniCel 
DxH 800. However, variable degrees of differences were observed during differential cell 
counting. For malignant cell analysis, the area under the curve was 0.63 for the XN-350 
analyzer and 0.76 for manual counting. We established our own reflex analysis guidelines 
as follows: HF-BFs <0.7/100 white blood cells (WBCs) is the criterion for quick scans 
with 100× magnification microscopic examination as a rule-out cut-off, while HF-BFs 
>83.4/100 WBCs or eosinophils >3.8% are the criteria for mandatory double check con-
firmation with 1,000× magnification examination.
Conclusions: The three automated analyzers showed good analytical performances. Ap-
plication of reflex analysis guidelines is recommended for eosinophils and HF-BFs, and 
manual confirmation is warranted.
Key Words: Body fluid, Automated cellular analyzer, Differential cell counting, UniCel DxH 
800, XN-350, UF-5000, Analytical performance
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INTRODUCTION
Body fluid (BF) cellular analysis provides physicians with exten-
sive and substantial information regarding patient medical con-
ditions, including inflammatory diseases, infection, hemorrhage, 
and malignancy [1-3]. BF analysis has been performed by 
manual counting using hemocytometer chamber methods [1, 
4], which has long been regarded as the gold standard [5-8]. 
However, manual counting is time-consuming, labor intensive, 
and subject to high inter-observer variability and potential poor 
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reproducibility [1-3, 8-10]. Automated analyzers are expected 
to improve precision and accuracy, reduce inter-observer vari-
ability, and shorten turn-around time [6, 11]. They have also 
shown acceptable performance and a good correlation with 
manual counting [3, 5-8, 11-14]. However, their limitations in-
clude poor precision at lower cell counts, lack of morphological 
differentiation, especially for malignant or clustered cells, and 
incomplete validation according to international standards [6, 8, 
9, 11, 15]. Hence, there remains an ongoing debate regarding 
the use of automated cellular analyzers versus manual counting 
[2]. Therefore, different laboratories might set up their own rules 
for BF analysis, combining automated cellular analyzer and 
manual counting [5].
In this study, we evaluated the analytical performance of three 
automated cellular analyzers for BF analysis: the UniCel DxH 
800 (Beckman Coulter, Brea, CA, USA), XN-350 (Sysmex, 
Kobe, Japan), and UF-5000 (Sysmex). To the best of our knowl-
edge, this is the first study to compare the analytical perfor-
mance of these three analyzers.
Beckman Coulter UniCel DxH 800 is a fully automated hema-
tology analyzer, which identifies cells using the Coulter tech-
nique based on the principle of impedance technology and light 
scatter analysis. For BF mode, the manufacturer recommends 
that a rinse cycle be performed using a diluent prior to analyze 
BF samples in order to ensure that the background total nucle-
ated cells (TNCs) and red blood cell (RBCs) counts are within 
acceptable limits [16].
Sysmex XN-350 is also an automated hematology analyzer. It 
aspirates only 70 μL of BF and uses fluorescence flow cytome-
try for TNCs and flow impedance technology for RBCs. TNCs 
include high-fluorescence BF cells (HF-BFs) that fall outside 
the white blood cell (WBC) differential fluorescence scattergram 
[10]. HF-BFs include macrophages, lining cells, such as meso-
thelial cells, atypical cells, and malignant cells. Moreover, it is a 
part of the Sysmex XN series that has been validated for BF 
analysis [5, 14].
Sysmex UF-5000 is a third-generation urine sediment ana-
lyzer that uses flow cytometry [17]. Each cell is stained with flu-
orescent dyes and passed through the flow lamina. The instru-
ment enumerates cells using the forward and side scatters and 
side fluorescent light [18]. The UF series has been validated for 
BF cellular analysis, including cerebrospinal fluid (CSF) [6, 18, 
19].
Our aims were the followings: (1) to investigate the basic per-
formance characteristics, including precision, linearity, and de-
tection capabilities, of the three automated analyzers; (2) to 
compare TNCs, WBCs, RBCs, and differential cell counts ob-
tained using the automated analyzers with the results obtained 
by manual counting as a reference method; and (3) to establish 
a workflow for BF analysis in our laboratory.
METHODS
Study samples
A total of 542 BF samples were collected prospectively from 
April to June 2016 from in- and outpatient samples submitted 
for routine BF analysis to the clinical laboratory of the Severance 
Hospital, Yonsei University, Seoul, Korea. These comprised 88 
CSF and 454 non-CSF samples, including 183 peritoneal, 130 
pleural, 104 continuous ambulatory peritoneal dialysis (CAPD), 
20 bronchoalveolar lavage (BAL), 10 pericardial, five synovial, 
and two cystic fluid samples. Immediately after receiving the 
sample for routine BF analysis, each sample was aliquoted into 
two tubes: 1.0 mL for manual counting and differential counting 
by microscopy and at least 1.4 mL for analysis using the three 
automated analyzers. CSF and non-CSF samples were collected 
in plain tubes and K2-EDTA anticoagulated tubes, respectively. 
All samples were analyzed within two hours once they were re-
ceived.
Manual microscopy
Manual microscopic counting was performed using a Neubauer 
hemocytometer. For non-CSF samples, TNCs and RBCs were 
counted from unstained and undiluted samples. For CSF sam-
ples, RBCs were counted in the same way; however, TNCs were 
counted using samples diluted 1:10 (50 μL CSF+450 μL of so-
lution) in Turk’s solution (crystal violet and glacial acetic acid 
dissolved in distilled water). Cell counting was performed at 
200× magnification using a standard light microscope. Two 
well-trained laboratory technologists performed the counting in-
dependently, and the average number was converted into cells/
μL according to the following formula provided in the CLSI H56-
A guidelines [4]:
  ce lls/μL=(N of cells counted×dilution factor)/(N of square 
mm counted×chamber depth)
wh ere 1 mm3 is equivalent to 1 μL, and the chamber depth 
was 0.1 mm.
For differential WBC counting, slides were prepared by cyto-
centrifugation of the samples followed by Wright-Giemsa stain-
ing. At least 100 cells were counted at 400× magnification. 
Neutrophils, eosinophils, and basophils were classified together 
as polymorphonuclear cells (PMNs). Lymphocytes, plasma cells, 
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and monocytes were classified together as mononuclear cells 
(MNs). Macrophages, lining cells, such as mesothelial cells, 
atypical cells, and malignant cells were counted as “other cells.”
Precision and linearity analysis
Using high and low cell number (TNCs and RBCs) QC samples 
provided by each vendor, precision analysis was carried out 
each day for 20 working days as two runs performed in dupli-
cate, separated by a minimum of two hours, according to the 
CLSI EP15-A2 [20]. The imprecision was calculated as 
mean±SD and CV (%).
To verify the TNC and RBC linear ranges for the three analyz-
ers, we performed linearity analyses with high (H) cell-count pa-
tient samples. Each sample was serially diluted with a recom-
mended diluent (D) to produce a total of five low-range concen-
trations: 0.75D+0.25H, 0.5D+0.5H, 0.25D+0.75H, 0.125D+ 
0.875H, and H. The five dilution concentrations were analyzed 
in duplicate. The decision criterion for acceptance was defined 
as a % residual (distance from each data point to the calculated 
linear fit target) for each concentration <10% except for the low-
est concentration, according to the CLSI EP06-A guidelines [21].
Detection capabilities: limit of blank (LoB), limit of detection 
(LoD), and limit of quantification (LoQ) verification
The LoB was determined with blank samples (UniCel DxH 800, 
vendor-provided diluent; XN-350, Cellpack; UF-5000, Cellsheath) 
measured at the beginning of the daily runs for 20 working 
days. The LoB was calculated as the mean value of the blank 
samples+(1.645×SD of blank samples) and the LoD was calcu-
lated according to the CLSI EP17-A2 [22]. The TNC LoQ was 
also assessed for the three analyzers, allowing a 15.49% total 
error, which was calculated as a root mean square of the intra-
assay CVs estimated by quadruplet analysis of 20 low-count 
samples; 15.49% is the within-patient variation for WBC counts 
based on the Westgard database of the desired specifications of 
biological variation [23].
Method comparison
A total of 542 BF samples were first measured by manual 
counting using a Neubauer hemocytometer. Next, they were 
analyzed using the UniCel DxH 800, XN-350, and UF-5000 au-
tomated analyzers. Passing-Bablok regression and Bland-Alt-
man analysis were used to compare the TNC counts, RBC 
counts, MNs, and PMNs obtained using the automated analyz-
ers with those obtained by manual counting, following the CLSI 
EP09-A2 guidelines [24]. The bias within±20% at the slope of 
the Passing-Bablok equation was considered “acceptable.” 
Establishment of reflex analysis guidelines using XN-350
Following an evaluation of the three automated cellular analyz-
ers, we developed reflex analysis guidelines for our laboratory. 
We examined each sample using both the manual method and 
XN-350, and the results obtained from the manual method 
were reported to the patient via the laboratory information sys-
tem (LIS). The WBC differential count results obtained from XN-
350 were not reported to the patient but were stored in the LIS 
as research parameters so that we could collect and confirm 
them. The WBC differential counts obtained using XN-350 were 
compared with those obtained by manual differential counting. 
The HF−BFs results obtained using XN-350 were compared 
with the BF cytology results. Data were collected retrospectively 
between September and November 2017 from the LIS and 
electronic medical records of Severance Hospital.
During that period, a total of 2,779 BF analysis results were 
reviewed retrospectively. In total, 803 BF results had corre-
sponding BF cytology results, including 369 peritoneal fluid, 362 
pleural fluid, 35 pericardial fluid, 17 BAL fluid, 10 cyst aspirate, 
three CAPD fluid, two CSF, one synovial fluid, and four other BF 
samples. The HF-BF results were compared with the cytology 
results using ROC curve analysis and the optimal cut-off values 
were assessed for discriminating malignancy-positive or negative 
samples. We defined true malignancy as a cytology report indi-
cating “positive or suspected malignancy.” If a cytology report 
showed only “atypical cells,” we considered it negative.
Ethical approval
In this study, we received two ethical approvals for two subsec-
tions separately. For the first subsection that was carried out 
from April to June 2016 using 542 BF samples, approval was 
obtained from the Institutional Review Board (IRB) of Severance 
Hospital (No. 1-2016-0011). For the second subsection that 
was carried out between September and November 2017 using 
our LIS data, another approval was obtained from the IRB (No. 
1-2018-0080). For both subsections, the requirement for in-
formed consent from patients was waived on condition that the 
samples were not individually identifiable and that patient pri-
vacy was thoroughly protected.
Statistics
Statistical analysis was performed using IBM SPSS Statistics for 
Windows, version 23.0 (IBM Corp., Armonk, NY, USA) and Mi-
crosoft Excel 2010 (Microsoft Corp., Redmond, Washington, 
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USA) with Analyse-it version 5.11 (Analyse-it Software Ltd., 
Leeds, UK). Detection capabilities were calculated according to 
the CLSI guidelines [22]. Passing-Bablok regression and Bland-
Altman analysis were used for method comparison. Diagnostic 
agreement of the XN-350 and manual microscopy compared to 
BF cytology was evaluated using receiver operating characteris-
tics (ROC) curves, and the area under curve (AUC) values were 
compared for the determination of the presence of malignant 
cells. For the establishment of reflex analysis guidelines using 
XN-350, the sensitivity, specificity, positive predictive value 
(PPV), negative predictive value (NPV), agreement rate (%), 
and kappa values were calculated according to various cut-off 
values. Additionally, the 95% confidence intervals (CIs) of each 
item were also calculated. P <0.05 was considered significant.
RESULTS
Analytical performance
The precision, linearity, and detection capability results are 
shown in Table 1. The within-device imprecision for TNC was 
5.6–9.3% for the low concentration control and 1.2–2.4% for 
the high concentration control. The within-device imprecision 
for RBC was 4.3–8.0% for the low concentration and 2.4–3.3% 
for the high concentration. TNC and RBC concentration lineari-
ties were verified using patient samples. The TNC and RBC de-
tection capabilities (LoB, LoD, and LOQ) using the three auto-
mated analyzers were verified (Supplemental Data Figure S1). 
Method comparison
The results of method comparisons are summarized in Table 2. 
All three automated analyzers showed acceptable performances 
(%bias within±20% at the slope of the Passing-Bablok equa-
tion) with manual counting, except for the RBC count in CSF 
samples using the UniCel DxH 800. The biases obtained by 
Bland-Altman analysis are also summarized in Table 2. For the 
PMN (%) and MN (%) differential count, the three automated 
analyzers showed different performances compared with man-
ual counting (Table 2). 
Establishment of reflex analysis guidelines using the XN-350
In an additional retrospective study, the Sysmex XN-350 showed 
acceptable performances with manual counting in terms of 
PMN, MN, neutrophil, lymphocyte, and monocyte percentages 
(Table 3). 
Although the slope was 2.50 (95% CI, 1.29–∞) for eosino-
phils and 1.60 (95% CI, 1.28–2.30) for HF-BFs, when we di-
vided the samples according to whether the eosinophil (%) 
counted by the manual method was >or <10% (used as a cut-
off point or an indicator of hypereosinophilia [25]), the XN-350 
ROC curve showed an AUC of 0.98 (95% CI, 0.96–0.99). At an 
eosinophil cut-off of 3.8%, XN-350 showed 95.9% sensitivity 
(95% CI, 89.9–98.4%) and 92.5% specificity (95% CI, 90.9–
93.8%) for hypereosinophilia (>10% eosinophils; Table 4) with 
99.7% NPV (95% CI, 99.1–99.9%) and 50.0% PPV (95% CI, 
45.0–55.0%).
Additionally, we compared the HF-BFs obtained by XN-350 
according to the presence of malignant cells determined by cy-
tology. The ROC curve of XN-350 showed an AUC of 0.63 (95% 
CI, 0.58–0.66; Fig. 1), a lower value than that of manual mi-
croscopy (0.76; 95% CI, 0.70–0.77; P <0.001). We also evalu-
ated the diagnostic performance depending on various HF-BF 
cut-off values for detecting potential malignancy. Although the 
Youden index showed a maximum sensitivity and specificity of 
67.0% (95% CI, 60.3–73.1%) and 52.7% (95% CI, 48.4–
56.9%), respectively, at a cut-off point of 5.9 HF-BFs/100 
WBCs, the accuracy was not sufficiently good (Table 5); there-
Table 1. TNC and RBC precision, linearity, and detection capabilities using three automated analyzers
Within-device SD (CV%) AMR Detection capability
Low Mid High Claimed Validated LoB LoD LoQ
UniCel DxH 800 TNC×109/L 0.125±0.012 (9.3) 1.382±0.060 (4.4) 65.676±0.791 (1.2) 0.020–89.000 9.501–38.005 0.012 0.018 0.037
RBC×1012/L 0.012±0.001 (4.3) 1.741±0.014 (0.8)   5.843±0.137 (2.4) 0.001–6.200 1.499–5.996 <0.001 <0.001 >0.005
XN-350 TNC×109/L 0.083±0.005 (5.6) -   0.324±0.008 (2.4) 0.003–10.000 2.629–10.517 <0.001 0.003 0.027
RBC×1012/L 0.026±0.002 (8.0) -   0.077±0.003 (3.3) 0.002–5.000 1.250–5.001 <0.001 <0.001 0.003
UF-5000 TNC×109/L 0.038±0.003 (6.7) -   0.796±0.017 (2.1) 0.001–10.000 2.354–9.416 <0.001 0.002 0.025
RBC×1012/L <0.001 (5.4) - <0.001 (3.2) 0.000–0.010 0.002–0.009 <0.001 <0.001 <0.001
UniCel DxH 800 (Beckman Coulter, Brea, CA, USA), XN-350 (Sysmex, Kobe, Japan), and UF-5000 (Sysmex, Kobe, Japan).
Abbreviations: TNC, total nucleated cell; RBC, red blood cell; AMR, analytical measurement range; LoB, limit of blank; LoD, limit of detection; LoQ, limit of 
quantification.
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Table 4. Diagnostic performance of high eosinophil (>10%) using XN-350 at various eosinophil (%) cut-off values (mean and 95% confi-
dence intervals)
Cut-off Sensitivity (%) Specificity (%) PPV (%) NPV (%) Accuracy (%) LR+ LR-
≥1.0 99.0 (94.4–99.8) 71.9 (69.3–74.3) 21.6 (20.1–23.2) 99.9 (99.2–99.9) 73.9 (68.0–79.7) 3.52 (3.22–3.86) 0.01 (0.00–0.08)
≥1.7 99.0 (94.4–99.8) 80.5 (78.3–82.7) 28.5 (26.2–30.9) 99.9 (99.3–99.9) 81.9 (75.2–88.5) 5.09 (4.54–5.71) 0.01 (0.00–0.01)
≥3.1 97.9 (92.8–99.4) 90.2 (88.5–91.8) 44.0 (39.8–48.2) 99.8 (99.3–99.9) 90.8 (83.1–98.5) 10.03 (8.46–11.92) 0.02 (0.01–0.02)
≥3.8 95.9 (89.9–98.4) 92.5 (90.9–93.8) 50.0 (45.0–55.0) 99.7 (99.1–99.9) 92.7 (84.8–99.9) 12.77 (10.47–15.60) 0.04 (0.01–0.10)
≥5.2 90.7 (83.3–95.0) 95.5 (94.2–96.5) 61.1 (54.7–67.2) 99.3 (98.6–99.6) 95.1 (86.8–99.9) 20.07 (15.43–26.12) 0.10 (0.05–0.17)
≥8.3 80.4 (71.4–87.1) 98.0 (97.0–98.6) 75.7 (67.6–82.3) 98.5 (97.7–99.0) 96.6 (88.1–99.9) 39.85 (26.78–59.33) 0.20 (0.13–0.29)
≥10.1 70.1 (60.4–78.3) 98.7 (97.9–99.2) 81.0 (72.0–87.6) 97.7 (96.9–98.3) 96.5 (87.9–99.9) 54.29 (32.97–89.40) 0.30 (0.22–0.40)
≥13.3 51.5 (43.7–63.2) 99.5 (98.8–99.8) 92.6 (79.3–97.2) 96.1 (95.7–97.1) 95.9 (87.4–99.9) 110.71 (46.86–245.97) 0.47 (0.37–0.57)
≥16.1 39.2 (30.1–49.1) 99.7 (99.2–99.9) 90.5 (77.6–96.3) 95.4 (94.7–96.1) 95.1 (86.5–99.9) 121.35 (45.98–320.40) 0.61 (0.51–0.70)
Abbreviations: PPV, positive predictive value; NPV, negative predictive value; LR+, positive likelihood ratio; LR-, negative likelihood ratio.
fore, lowered or elevated cut-off values may be useful to rule-out 
or rule-in purposes, respectively.
Based on these findings, we developed the reflex analysis 
guidelines for our laboratory. The HF-BF cut-off point with 95% 
sensitivity was set at 0.7 HF-BFs/100 WBCs with 91.1% NPV 
(95% CI, 84.6–95.1%) and the HF-BF cut-off point with 95% 
specificity was set at 83.4 HF-BFs/100 WBCs with 77.8% PPV 
(95% CI, 55.5–88.5%). As mentioned above, an eosinophil cut-
off of 3.8% showed both high sensitivity and specificity. Based 
on these results, the following criteria were developed for estab-
lishing malignant cell positivity or the presence of significant eo-
sinophilia (>10% eosinophils):
Rule 1 (HF-BFs <0.7/100 WBCs): the criterion for quick 
scans at 100× magnification microscopic examination as a 
rule-out cut-off without any confirmation from the clinical pa-
thologist.
Rule 2 (HF-BFs >83.4/100 WBCs): the criterion for 1,000× 
magnification microscopic examination with mandatory clinical 
pathologist confirmation.
Rule 3 (Eosinophils >3.8%): the criterion for 1,000× magni-
fication manual counting.
When the HF-BFs were between 0.7 and 83.4/100 WBCs, slide 
scanning at 1,000× magnification microscopic examination with 
clinical pathologist confirmation is indicated for cases of suspected 
malignant cells. The proportion of positive samples for each rule 
was as follows: 85.9% (N=690) for rule 1, 11.5% (N=92) for rule 
2, 15.1% (N=121) for rule 3, 87.9% (N=706) for both rules 1 
and 3, and 17.1% (N=137) for both rules 2 and 3.
DISCUSSION
We evaluated the analytical performance of three automated 
cellular analyzers: the Beckman Coulter UniCel DxH 800, the 
Sysmex XN-350, and the Sysmex UF-5000. These automated 
Fig. 1. ROC curve analysis of HF-BFs obtained using the Sysmex 
XN-350 and other cells obtained by manual counting compared 
with positive results (positive for malignancy and atypical cells) de-
termined by cytology. Lining cells and monocytes/histiocytes were 
classified together as MNs. Macrophages, lining cells, such as me-
sothelial cells, atypical cells, and malignant cells were counted as 
“other cells.”
Abbreviations: HF-BFs, high fluorescence-body fluid cells; TPF, true positive 
fraction; FPF, false positive fraction; AUC, area under the curve; CI, confi-
dence interval; MNs, mononuclear cells.
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Table 5. Diagnostic performance according to various HF-BFs/100 WBCs cut-off values obtained using XN-350 for detection of potential 
malignancy (mean and 95% confidence intervals)
Cut-off Sensitivity (%) Specificity (%) PPV (%) NPV (%) Accuracy (%) LR+ LR-
>0.7 95.1 (91.2–97.3) 19.6 (16.4–23.2) 31.4 (30.2–32.5) 91.1 (84.6–95.1) 40.6 (35.6–45.4) 1.18 (1.12–1.25) 0.25 (0.14–0.46)
≥2.6 81.8 (75.9–86.5) 36.3 (32.3–40.5) 33.2 (31.1–35.2) 83.7 (79.1–87.6) 49.0 (45.7–52.3) 1.28 (1.17–1.40) 0.50 (0.37–0.68)
≥4.3 71.4 (64.9–77.2) 45.1 (40.9–49.3) 33.5 (30.9–36.0) 80.3 (76.3–83.8) 52.4 (49.7–55.1) 1.30 (1.15–1.46) 0.63 (0.49–0.79)
≥5.9 67.0 (60.3–73.1) 52.7 (48.4–56.9) 35.4 (32.4–38.4) 80.5 (77.0–83.6) 56.7 (54.0–59.3) 1.42 (1.24–1.61) 0.63 (0.50–0.77)
≥8.7 52.2 (45.4–59.0) 63.7 (59.5–67.7) 35.7 (31.8–39.8) 77.5 (74.7–80.2) 60.5 (57.5–63.5) 1.44 (1.20–1.70) 0.75 (0.64–0.87)
≥12.3 42.4 (35.8–49.2) 72.1 (68.1–75.7) 37.0 (32.1–41.9) 76.4 (74.0–78.7) 63.8 (60.2–67.4) 1.52 (1.22–1.87) 0.80 (0.70–0.90)
≥15.8 33.0 (26.9–39.7) 78.1 (74.4–81.5) 36.9 (31.1–42.9) 75.1 (73.1–77.1) 65.6 (61.4–69.7) 1.51 (1.17–1.94) 0.86 (0.77–0.95)
≥20.3 22.7 (17.4–28.9) 84.8 (81.5–87.6) 36.6 (29.4–44.3) 73.9 (72.3–75.5) 67.5 (62.6–72.4) 1.49 (1.07–2.05) 0.91 (0.83–0.99)
≥48.2 11.8 (8.1–17.0) 97.1 (95.3–98.3) 61.6 (46.1–74.9) 74.0 (73.0–75.1) 73.4 (67.2–79.6) 4.15 (2.24–7.66) 0.91 (0.85–0.95)
≥54.8 11.3 (7.7–16.4) 97.9 (96.3–98.8) 67.7 (50.9–80.8) 74.1 (73.1–75.1) 73.8 (67.5–80.1) 5.42 (2.73–10.76) 0.91 (0.85–0.95)
≥83.4 6.9 (4.2–11.2) 99.2 (97.8–99.6) 77.8 (55.5–88.5) 73.4 (72.6–74.1) 73.5 (66.9–79.9) 9.07 (2.75–19.14) 0.94 (0.90–0.97)
Abbreviations: see Table 4.
analyzers showed good within-device precision. The lower limit 
of analytical measurement range of the UniCel DxH 800 was 
relatively higher than that of the other two analyzers, but their 
linearity was satisfactory compared with the manufacturer-pro-
vided analytical measurement range. The UniCel DxH 800 
showed relatively higher LoB and LoD values for TNC, at 
0.012×109/L and 0.018×109/L, respectively; however, both 
were within the limit claimed by the manufacturer. The TNC 
LoQ values were comparable across instruments, at 0.037×109/
L for the UniCel DxH 800, 0.027×109/L for the XN-350, and 
0.025×109/L for the UF-5000. These results were similar to 
previous findings [3, 11, 18], and the LoQ has been reported to 
range from 0.010 to 0.030 TNCs×109/L [1]. As the LOQ was 
>0.024×109/L using both XN-350 and UF-5000, we could not 
use these analyzers for screening TNC counts in CSF because 
the standard reference cut-off for CSF is 5/μL [11, 19].
The results of method comparisons for TNC and RBC counts 
were satisfactory in terms of the slopes of the Passing-Bablok 
equations, except for the RBC count in CSF samples using the 
UniCel DxH 800 (slope of 1.41 [95% CI, 1.10–2.14]). However, 
in cases of non-CSF samples, the UniCel DxH 800 showed sat-
isfactory and similar results compared with the other analyzers. 
For PMN (%) and MN (%) differential counts, XN-350 showed 
the most comparable results to those of manual differential 
counting in both CSF and non-CSF samples; the UniCel DxH 
800 and UF-5000 showed negative bias compared with manual 
counting (Table 2). Prior to the launch of a new automated BF 
analysis mode for the XN series or UF-5000, the UniCel DxH 
800 BF analysis mode was used for samples with higher RBC 
or WBC counts to reduce the workload of manual counting in 
spite of its limitations. Beckman Coulter states that the back-
ground count for RBCs and TNCs is 0.001×1012/L and 0.020× 
109/L, respectively; however, Sysmex states that the background 
count for RBCs and TNCs for the XN series is <0.001×1012/L 
and <0.001×109/L, respectively. The higher sensitivity at low 
TNC and RBC concentrations may be due to differences in the 
measurement principles, the fluorescent flow cytometric method 
of Sysmex vs. Coulter VCS (volume, conductivity, and scattering 
of light) technology. Further multicenter studies are required to 
demonstrate more accurate and reliable comparison results. 
However, as the performance of the UniCel DxH 800 was also 
acceptable for the TNC and RBC counts in non-CSF samples 
and the TNC counts in CSF samples, clinical use of the UniCel 
DxH 800 is possible with acceptable performance.
Additional analyses using XN-350 also showed satisfactory re-
sults for neutrophils (%) and lymphocytes (%). The XN-350 
monocyte (%) results were approximately 26.5% lower than the 
manual counting results; however, the MN (%) results showed 
good correlation with manual counting, with a Passing-Bablok 
equation slope of 0.94 (Table 3). The XN-350 eosinophil (%) 
and HF-BF results showed poor agreement and significant bias 
with manual counting. Therefore, we tried to establish a cut-off 
value for further microscopic review. An eosinophil (%) >10% 
of WBCs is a potential indicator of pulmonary embolism, pneu-
mothorax, parasitic disease, and Churg-Strauss syndrome [25]. 
Thus, we considered 10% eosinophils obtained by manual 
counting as significant eosinophilia; an eosinophil cut-off point 
of 3.8% using XN-350 was determined as an acceptable crite-
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rion with 99.7% NPV and 50.0% PPV for further microscopic 
review (Table 4). Overestimation of eosinophils using XN-350 
may be due to interference by eosinophilic granules or mistak-
ing hypergranulated neutrophils as eosinophils. However, as few 
studies have examined this phenomenon, further studies are 
needed [5].
Additionally, we compared the HF-BFs, at the cut-off point of 
5.9 HF-BFs/100 WBCs obtained using the Sysmex XN-350 ac-
cording to the presence of malignant cells determined by the 
Youden index with maximum sensitivity and specificity (67.0% 
and 52.7%, respectively). This cut-off point was similar to the 
6.9 HF-BFs/100 WBCs reported by Cho, et al. [8], but higher 
than the 2.1 HF-BFs/100 WBCs reported by Labaere, et al. [15]. 
Compared with these previous studies, the sensitivities and 
specificities at various cut-offs in the present study were lower, 
probably due to the use of different gold standards, sample vari-
ability, pre-analytical variables, inter-observer variability, or ag-
gregation of malignant cells [1, 15]. However, different cut-off 
values according to a specific purpose may be helpful. For ex-
ample, 83.4 HF-BFs/100 WBCs or higher could be used as a 
rule-in cut-off, as the positive likelihood ratio (LR)(+) value is 
9.07 (95% CI, 2.75–19.14) and 77.8% PPV (95% CI, 55.5–
88.5%), while ≤0.7 HF-BFs/100 WBCs could be used as a 
rule-out cutoff, as the LR(-) value is 0.25 (95% CI, 0.14–0.46) 
(Table 5) and 91.1% NPV (95% CI, 84.6–95.1%). Results 
>83.4 HF-BFs/100 WBCs indicate the need for careful slide 
examination at 400× and/or 1,000× magnification, while re-
sults <0.7 HF-BFs/100 WBCs indicate that the slide can be ex-
amined at 100× or 200× magnification for a quick review.
The limitations of this study are that (1) the BF samples may 
have remained unattended for a considerable time at room tem-
perature (22–27°C) at the collection site before transport to the 
central clinical laboratory. As we did not record the time be-
tween sample collection and receiving them in laboratory, we 
cannot guarantee that all samples were fresh; however, we ana-
lyzed the samples within two hours once they were received in 
the laboratory; (2) The gold standard was the cytological report 
rather than biopsy results because of the unavailability of biopsy 
samples in the pathological examinations; (3) Samples with high 
HF-BFs may be due to macrophage or mesothelial cells, as well 
as malignant cells. However, we did not distinguish malignant 
cells from other cell types in other cell categories; (4) Finally, the 
additional retrospective study using XN-350 showed that there 
were 1,015 CSF results of the 2,779 BF results; however, as 
most of them did not have corresponding BF cytology results, 
we obtained only two CSF results. 
In conclusion, we evaluated the analytical performance of 
three automated cellular analyzers and compared them with 
manual counting. While recent automated analyzers have shown 
good agreement in terms of TNC and RBC counting, there are 
differences in differential counting. Because of poor correlation, 
especially for eosinophils and HF-BFs, the application of specific 
reflex analysis guidelines is recommended for clinical laborato-
ries, and manual confirmation is warranted to ensure accuracy 
compared with morphological and clinical aspects.
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Supplemental Data Figure S1. Relationship between total error 
(%) calculated by root mean square and TNCs using three auto-
mated body fluid cellular analyzers: (A) UniCel DxH 800, (B) XN-
350, and (C) UF-5000. The limit of quantification was calculated 
according to the formula for TE (%), RMS, and TNC, where the TE 
(%)_RMS was 15.49%.
Abbreviations: TNCs, total nucleated cells; TE (%)_RMS, total error (%) by 
root mean squares; TE=sqrt(s2+Bias2); s, observed standard deviation; 
bias, observed value against reference method (Neubauer chamber).
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